EHA to the European Commission and HTA leaders: work with medical societies to i...

20220622 HTA Conference speakers

The speakers of the HTA conference hosted by the European Commission. Photo credit: European Commission

Read more

EU funding approved for TOLERATE

AdobeStock 68767205

On April 1, the European Commission approved funding for the TOLERATE training network, proposed by a KU Leuven-led consortium including EHA.

Read more

EU pilot on drug repurposing

AdobeStock 276764998

Drug repurposing (finding new indications for existing authorized medicines) is increasingly prominent in the debate about improving access to medicines.

Read more

EU Calls for Proposal 2022

AdobeStock 353450686

Spurred by COVID-19 and rising challenges to the financial sustainability of Europe’s health systems, a flurry of new EU policies and programs in health has sprung up since last year.

Read more

EU Calls for proposal 2021

call for proposals cropped

Spurred by COVID-19 and rising challenges to the financial sustainability of Europe’s health systems, a flurry of new EU policies and programs in health has sprung up since last year. Some of the most eye-catching initiatives are highly relevant for hematology: the Europe’s Beating Cancer Plan, the Pharmaceutical Strategy and the European Health Data Space.

Read more

EHA has joined the European Cancer Organisation - a perfect match on objectives ...

Member Society badge 1501x1136

The European Hematology Association (EHA) has joined the European Cancer Organisation, a not-for-profit federation of organizations working in cancer at the European level. EHA’s membership application was approved by the General Assembly of the European Cancer Organisation on November 18, 2020.

Read more

Call for urgent action on medicine shortages in Europe

michal parzuchowski 7TWRwDjfGew unsplash

EPHA published a position paper on medicine shortages in Europe. EHA welcomes its  recommendations to address the increasing shortages crisis, which threatens patient outcomes and patient safety.

Read more

ATMPs and CAR-T: the uptake challenge

HemAffairs ATMPs and CAR T

Advanced therapy medicinal products (ATMPs) are a game changer for improving the lives of patients with severe to life-threatening diseases. Yet, despite fast-paced innovation in the field, few ATMPs have reached the EU market and benefited patients. The challenges facing their adoption by health systems are complex. A test case is the uptake of CAR T-cell therapy; what are the hurdles and what action is needed from stakeholders?

Read more

EU health policy: limited scope, high ambition

HemAffairs EU health policy

While health policy remains the primary responsibility of Member States, in many areas the added value of EU-level collaboration and harmonization has increased. EU initiatives in health have shown a mixed record in terms of impact, but hopes are high for the latest one, the ambitious Europe’s Beating Cancer Plan.

Read more

Revising the ICH Guidelines on Clinical Trials

Delegation HemAffairs

Clinical trials and drug development have become more complex over the years. One complicating factor is the increased administrative burden, as was pointed out in the previous edition of HemAffairs. Doctors and clinical researchers are more and more bound to rules they deem neither necessary nor effective. At first sight, the requirements for clinical trials seem clear and thorough. Nonetheless, the interpretation and implementation of these rules leave room for improvement.

Read more

The past and future of the EU Blood, Tissues and Cells legislation

Annake HemAffairs HR

Blood, tissues and cells (BTC) are used in medicine and in hematology on a daily basis. EU legislation has been in place for over 15 years to regulate those practices, and to ensure safety and quality standards for substances of human origin (SoHO). For instance, through technical and traceability requirements for BTC, the reporting of serious adverse reactions (SARs), and verification procedures for imported BTC.

Read more

EHA at ICH meeting: Excessive bureaucracy harms patient safety and innovation

EHA delegation to ICH public meeting

To solicit input from a wide range of non-ICH members about the revision of ICH E8(R1), ICH held a Public Meeting on ICH E8(R1) “General Considerations for Clinical Studies” (Silver Spring, USA, October 31, 2019).

Read more

EHA’s Prof Jäger elected HCPWP co-chair

HCPWP co chairs Prof. Ulrich Jaeger EHA and Juan Garcia Burgos EMA

On September 24, Prof Ulrich Jäger, former EHA President and current member of the EHA European Affairs Committee, was elected as co-chair of the Health Care Professionals Working Party (HCPWP) of the European Medicines Agency (EMA). He will lead the working party during its 2019-2022 mandate alongside Juan Garcia-Burgos, EMA’s head of Public Engagement.

Read more

Without access to treatment, can we truly innovate in rare diseases?

HemAffairs Sept 24 v2

There have been many developments on rare diseases since the EU Orphan Medicinal Products Regulation came into force in 2000. As the European Commission is evaluating its effectiveness, EHA discussed with Prof. Giampaolo Merlini, Director of the Amyloidosis Research and Treatment Center and researcher at the Department of Molecular Medicine of the University of Pavia, how far we have come and what still needs to be done to improve access to treatment for rare diseases.

Read more

COST Action ‘EuNet-INNOCHRON’

HemAffairs Oct 3

The European Cooperation in Science and Technology (COST) is an EU-funded, intergovernmental framework that aims to create pan-European research networks in all science fields and promote excellence, foster interdisciplinary research and empower young researchers and innovators.

Read more